Pediatric Blood & Cancer · 2015 · 90 citations · 20 references
MedicineDermatologyPathologyDermatopathologyHistopathologyPediatric DermatologyCutaneous NeoplasmsImmunopathology Of SkinNeoplastic Skin LesionsPediatric DermatopathologySkin TumorsBraf V600 MutationsBraf V600e MutationCutaneous HistiocytosisDermatopathologic Lesion DescriptionMultisystem Langerhans Cell HistiocytosisPatient-reported Skin SymptomsPediatric Skin PathologyPrimary Skin Lesions
BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare disease, frequently affecting young children. PROCEDURE: We performed a retrospective study in patients younger than 16 years old manifesting with skin symptoms, and documented their different cutaneous lesions and systemic symptoms. We compared subgroups of children with single-system, skin-only, and multisystem disease and sought signs predictive for multisystem disease. In a small sample of patients, BRAF mutations were analyzed in archived biopsies. RESULTS: A wide spectrum of cutaneous presentations varying from crusted nodules and papules, blisters, vascular tumor-like lesions, scaling orange to red macules (frequently in seborrheic regions) to purpuric macules, and papules was documented in our cohort of 32 children. Otitis externa was a common manifestation and mucosal lesions were seen in three patients. A novel manifestation was a red-blue nodule that appeared in a patient after a vaccination. None of the cutaneous lesions was predictive for the classification or final outcome as a single-system or multisystem disease. However, later onset and a more protracted course of skin lesions were more frequent findings in multisystem LCH. Mucosal lesions and otitis externa were almost exclusively seen in patients with multisystem disease, a finding that warrants further investigation. Both wild-type (WT) and mutated BRAF were found not only in multisystem LCH, but also in skin-only LCH. Two cases with rapidly resolving congenital lesions had WT BRAF. CONCLUSIONS: Late onset and a protracted course of skin lesions are associated with MS-LCH, whereas WT BRAF is found in rapidly resolving skin lesions.
20
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis
Helmut Gadner, Milen Minkov, Nicole Grois et al. · Blood · 2013 · 450 citations · Full text
Medicine, Immunology, Pathology +11
High prevalence of somatic MAP2K1 mutations in BRAF V600E–negative Langerhans cell histiocytosis
Noah A. Brown, Larissa V. Furtado, Bryan L. Betz et al. · Blood · 2014 · 367 citations · Full text